Published in TB and Outbreaks Week, February 2nd, 2010
"All previous evaluations of ST-246 efficacy have been in immunocompetent animals. However, the risk of severe poxviral disease is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.